JPM 2026
Taiwan’s Biotech Leaders Double Down on AI and US Manufacturing: Inside Bora and EirGenix’s Strategic Roadmaps
2026-02-03
[Illustrations] Global Blockbuster Drug Landscape Shifts in 2026: Keytruda Defends No. 1, “Diabesity” Rivals Surge, IRA Price Caps Take Effect
2026-01-22
From Capacity Upgrades to Tech Licensing: Global Strategies of Samsung Biologics, Celltrion, and Alteogen
2026-01-21
JPM 2026 Reveals Biopharma’s High-Stakes Mix of IPO Risk, Market Turbulence, and Regulation
2026-01-19
Beyond the Main Stage: A Showcase of the Next Wave of Korean Biotech Innovation at JPM Week 2026
2026-01-15
JPM 2026 Recap: Capital Markets Reopen, AI Moves to the Last Mile, Metabolic Stakes Climb
2026-01-15
JP Morgan 2026: Eight Companies’ Clinical Milestones across tRNA Medicines, Immune Reset, and Oncology
2026-01-13
From Main Venue Presentations to Strategic Partnering, Taiwan’s Biotech Sector Makes Its Mark in JPM 2026
2026-01-13



